Copyright
©The Author(s) 2017.
World J Transplant. Jun 24, 2017; 7(3): 161-178
Published online Jun 24, 2017. doi: 10.5500/wjt.v7.i3.161
Published online Jun 24, 2017. doi: 10.5500/wjt.v7.i3.161
Table 1 Definition and principal characteristics of biomarkers
Biomarker | A characteristic objectively measured as an indicator of a biological process or a response to a pharmacological intervention |
Proteomics | The systematic analysis of proteins for their identity, quantity and function |
Genomics | The study of the genome for estimating the risk for an individual to develop a disease |
Transcriptomics | The study of expression patterns of all gene transcript |
Metabolomics | The quantitative analysis of all the metabolites of a specific biological sample |
Table 2 Biomarker candidates in the context of ischemia reperfusion injury and delayed graft function
Symbol | Gene description | Cytoband |
ACTA2 | Actin, alpha 2, smooth muscle, aorta | 10q23.31 |
UMOD | Uromodulin | 16p12.3 |
LGALS3 | Lectin, galactoside-binding, soluble, 3 | 14q22.3 |
SAT1 | Spermidine/spermine N1-acetyltransferase 1 | Xp22.11 |
HAVCR1 | Hepatitis A virus cellular receptor 1 | 5q33.3 |
CXCL1 | Chemokine (C-X-C motif) ligand 1 | 4q13.3 |
ANXA2 | Annexin A2 | 15q22.2 |
S100A6 | S100 calcium binding protein A6 | 1q21.3 |
CYR61 | Cysteine rich angiogenic inducer 61 | 1p22.3 |
S100B | S100 calcium binding protein B | 21q22.3 |
AMBP | Alpha-1-microglobulin/bikunin precursor | 9q32 |
LCN2 | Lipocalin 2 | 9q34.11 |
C3 | Complement component 3 | 19p13.3 |
FABP1 | Fatty acid binding protein 1, liver | 2p11.2 |
ATF3 | Activating transcription factor 3 | 1q32.3 |
NTN1 | Netrin 1 | 17p13.1 |
ENG | Endoglin | 9q34.11 |
GUCY2G | Guanylate cyclase 2G | 10q25.2 |
BID | BH3 interacting domain death agonist | 22q11.21 |
BCL2 | B-Cell CLL/lymphoma 2 | 18q21.33 |
BAX | BCL2 associated X protein | 19q13.33 |
PTGS2 | Prostaglandin-endoperoxide synthase 2 | 1q31.1 |
ADAMTS1 | ADAM metallopeptidase with thrombospondin type 1 motif 1 | 21q21.3 |
CDKN1A | Cyclin dependent kinase inhibitor 1A | 6p21.2 |
Table 3 Unbiased proteomic studies for acute rejection
Ref. | Biomarker candidate | Sample type | Sample numbers | Outcome |
Freue et al[69] | TTN, LBP, CFD, MBL2, SERPINA10, AFM, KNG1, LCAT, SHBG | Plasma | 32 | AR |
Sigdel et al[70] | UMOD, PEDF, CD44 | Urine | 60 | AR |
Wu et al[71] | NF-κB, STAT1, STAT3 and 63 other proteins | Plasma | 13 | AR |
Loftheim et al[72] | IGFBP7, VASN, EGF, LG3BP | Urine | 12 | AR |
Sigdel et al[73] | HLA-DRB1, FGB, FGA, KRT14, HIST1H4B, ACTB, KRT7, DPP4 | Urine | 154 | AR |
Table 4 Selected promising molecules and pathways evaluated as biomarkers in acute rejection[7]
Biomarker | Sample (assay method) | Patients/samples | Rejection/no rejection | Sensitivity/specificity (%) | PPV/NPV(%) | AUC |
Granzyme B, perforin and FasL[74] | PBL (PCR) | 25/31 | 11/20 | 100/95 | 100/95 | NA |
FOXP3[88] | PBL, urine (PCR) | 65/78 | 20/58 | 94-100/95/100 | 94-100/95/100 | 0.95-1.00 |
Granzyme B, perforin[75] | Urine (PCR) | 85/151 | 24/127 | 79-83/77-83 | NA | NA |
OX40, OX40L, PD-1 and FOXP3[76] | Urine (PCR) | 46/46 | 21/25 | 95/92 | NA | 0.98 |
CD3ε,CXCL10, 18S rRNA[77] | Urine (PCR) | 485/4300 | 43/1,70 | 79/78 (71/72) | NA | 0.85 (0.74) |
TIM-3[81] | PBL, urine (PCR) | 115/160 | 65/95 | 87-100/95-100 | 87-100/93-100 | 0.96-1.00 |
CXCL9, CXCL10[78] | Urine (multiplex bead assay) | 156/156 | 25/131 | 80-86/76-80 | NA | 0.83-0.87 |
CXCL9 mRNA and protein[79] | PBL, urine (PCR, ELISA, SELDI-TOF-MS | 280/2770 | 37/113 | 66.7-85.2/ 79.6/80.7 | 61.5/67.6/83-92 | 0.78-0.85 |
miR-142-5p | Biopsy sample (PCR) | 32/33 | 12/21 | 92-100/90-95 | NA | 0.96-0.99 |
miR-155 | ||||||
miR-223[83] | ||||||
miR-210[85] | Urine (PCR) | 81/88 | 68/20 | 52/74 | NA | 0.7 |
IFNγ-producing memory T cells[89] | PBL (ELISPOT) | 23/23 | 12/10 | 80/83 | NA | 0.8 |
Table 5 Seventeen genes involved in the study kidney solid organ response test
Symbol | Gene name | Cytoband |
Genes derived from the NIH SNSO1 study | ||
DUSP1 | Dual-specificity phosphatase 1 | 5q35.1 |
NAMPT | Nicotinamide phosphoribosyltransferase | 7q22.3 |
PSEN1 | Presenilin 1 | 14q24.2 |
MAPK9 | Mitogen-activated protein kinase 9 | 5q35.3 |
NKTR | Natural killer cell triggering receptor | 3p22.1 |
CFLAR | CASP8 and FADD like apoptosis regulator gene | 2q33.1 |
IFNGR1 | Ligand binding chain of the gamma interferon receptor gene | 6q23.3 |
ITGAX | Integrin alphaXchain protein encoding gene | 16p11.2 |
RNF130 | Ring finger motif encoding gene | 5q35.3 |
RYBP | RING1 and YY1 binding protein encoding gene | 3p13 |
Genes added to improve the accuracy of kSORT | ||
CEACAM4 | Carcinoembryonic antigen related cell adhesion molecule 4 | 19q13.2 |
EPOR | Erythropoietin receptor encoding gene | 19p13.2 |
GZMK | Granzyme K encoding gene | 5q11.2 |
RARA | Retinoic acid receptor encoding gene | 17q21.2 |
RHEB | Ras homolog enriched in brain encoding gene | 7q36.1 |
RXRA | Retinoic X receptor alpha encoding gene | 9q34.2 |
SLC25A37 | Solute carrier family 25 number 37 encoding gene | 8p21.2 |
Table 6 Performance of kidney solid organ response test in the acute rejection in renal transplantation AART143, AART124, and AART100 cohorts
kSORT predictions | ||||||
AART143 (training set) | AART124 (validation set) | AART100 (cross-validation set) | ||||
AR | No AR | AR | No AR | AR | No AR | |
Real results | 3 | |||||
AR | 39 | 8 | 21 | 2 | 36 | 43 |
No AR | 9 | 87 | 1 | 100 | 3 | |
Sensitivity (95%CI) | 82.98% (69.19%-92.35%) | 91.30% (71.96%-98.38%) | 92.31% (79.13%-98.38%) | |||
Specificity (95%CI) | 90.63% (82.95%-95.62%) | 99.01% (94.61%-99.97%) | 93.48% (82.1%-96.63%) | |||
PPV (95%CI) | 81.25% (68.06%-89.81%) | 95.46% (78.20%-99.19%) | 93.21% (79.68%-97.35%) | |||
NPV (95%CI) | 91.58% (84.25%-95.67%) | 98.04% (93.13%-99.46%) | 93.48% (82.45%-97.76%) | |||
AUC (95%CI) | 0.94 (0.91-0.98) | 0.95 (0.88-1.00) | 0.92 (0.86-0.98) |
Table 7 Eleven genes overexpressed in the common rejection module[103]
Symbol | Gene name | Cytoband |
BASP1 | Brain abundant membrane attached signal protein 1 | 5p15.1 |
CD6 | CD6 molecule | 11q12.2 |
CXCL10 | C-X-C Motif chemokine ligand 10 | 4q21.1 |
CXCL9 | C-X-C Motif chemokine ligand 9 | 4q21.1 |
INPP5D | Inositol polyphosphate-5-phosphatase D | 2q37.1 |
ISG20 | Interferon stimulated exonuclease gene 20 | 15q26.1 |
LCK | LCK protooncogene, SRC family tyrosine kinase | 1p35.2 |
NKG7 | Natural killer cell granule protein 7 | 19q13.41 |
PSMB9 | Proteasome subunit beta 9 | 6p21.32 |
RUNX3 | Runt related transcription factor 3 | 1p36.11 |
TAP1 | Transporter 1, ATP binding cassette subfamily B member | 6p21.32 |
Table 8 Analysis of pooled urine proteins collected from patients with acute rejection, BK virus nephropathy, and chronic allograft nephropathy when compared to STA urine with the criteria of > 1.5 fold change of each transplant injury phenotype (acute rejection, BK virus nephropathy, and chronic allograft nephropathy), compared to STA pooled urine and with a P-value of ≤ 0.05[131]
Increased in AR | Increased in BKVN | Increased in CAN |
HLA-DRB1, FGB, FGA, FGG, KRT14, HIST1H4B, KRT7, DPP4 | KRT18, SUMO2, STMN1, CFHR2, KRT8, KRT19, RPL18, KRT75, FAM3C, HIST1H2BA | CALR, FAM151A, SERPINA2P, FAM3C, DAG1, KITLG, LUM, FABP4, AGT, LRG1 |
Table 9 Genes higher (fold change higher than 6.00) expressed in renal tissue of patients affected by interstitial fibrosis/tubular atrophy[119]
Symbol | Gene name | Cytoband |
IGHA1 | Immunoglobulin heavy constant alpha 1 | 14q32.33 |
IGHG1 | Immunoglobulin heavy constant gamma 1 | 14q32.33 |
CCR2 | Chemokine C-C motif receptor 2 | 3p21.31 |
DFFB | DNA fragmentation factor 40 Da beta subunit | 1p36.32 |
CD44 | CD44 antigen | 11p13 |
IFNA1 | Interferon alpha 1 | 9p21.3 |
GZMK | Granzyme K | 5q11.2 |
MMP9 | Matrix metallopeptidase 9 | 20q13.12 |
TNFRSF17 | Tumor necrosis factor receptor superfamily, member 17 | 16p13.13 |
CXCR4 | Chemokine C-X-C motif receptor 4 | 2q22.1 |
Table 10 Thirteen genes associated with chronic allograft dysfunction identified by biopsy transcriptome expression[121]
Symbol | Gene description | Cytoband | CADI 12 mo correlation | P value |
CHCHD10 | Coiled-coil-helix-coiled- coil helix domain containing 10 | 22q11.23 | 0.404 | 2.85 × 10-5 |
KLHL13 | Kelch-like family member 13 | Xq23-q24 | 0.369 | 1.49 × 10-4 |
FJX1 | Four jointed box 1 | 11p13 | 0.367 | 1.60 × 10-4 |
MET | Met proto-oncogene | 7q31 | 0.352 | 3.01 × 10-4 |
SERINC5 | Serine incorporator 5 | 5q14.1 | 0.318 | 0.0012 |
RNF149 | Ring finger protein 149 | 2q11.2 | 0.28 | 0.0046 |
SPRY4 | Sprouty homolog 4 | 5q31.3 | 0.27 | 0.0062 |
TGIF1 | TGF-β induced factor homeobox 1 | 18p11.3 | 0.244 | 0.0140 |
KAAG1 | Kidney associated antigen 1 | 6p22.1 | 0.24 | 0.0154 |
ST5 | Suppressor of tumorigenicity 5 | 11p15 | 0.232 | 0.0197 |
WNT9A | Wingless-type MMTV integration site family member 9A | 1q42 | 0.212 | 0.0332 |
ASB15 | Ankirin repeat and SOCS box-containing 15 | 7q31.31 | -263 | 0.0079 |
RXRA | Retinoid X receptor alpha | 9q34.3 | -0.3 | 0.0023 |
Table 11 International research consortia in rejection/tolerance
Acronym | Description | Year |
ITN | Immune tolerance network | Since 2002 |
IOC | Indices of tolerance | 2003-2007 |
RISET | Reprogramming the immune system for establishment of tolerance | 2005-2010 |
GAMBIT Study | Genetic analysis and monitoring of biomarkers of immunological tolerance | 2010 |
The One Study | A unified approach to evaluating cellular immunotherapy in solid organ transplantation | 2011 |
Bio-DRIM | Personalized minimization or immunosuppression after solid organ transplantation by biomarker driven stratification of patients to improve the long-term outcome and health-economic data of transplantation | 2012 |
BIOMARGIN | Biomarkers of renal graft injuries in kidney allograft recipients | 2013 |
Table 12 Immune/inflammatory molecules among the 357 gene signatures of tolerance
Categories | Diseases or functions annotation | Molecules | No. of molecules |
Cell-to-cell signaling and interaction, cellular function and maintenance, hematological system development and function, inflammatory response | Phagocytosis of leukocyte cell lines | FGR, MRC1, TLR4 | 3 |
Cell-to-cell signaling and interaction, hematological system development and function, immune cell trafficking, inflammatory response, tissue development | Binding of neutrophils | FGR, LSP1, TLR4 | 3 |
Antimicrobial response, inflammatory response | Antibacterial response | CARD9, FGR, LYST, NLRC4, TLR4 | 5 |
Cell-to-cell signaling and interaction, hematological system development and function, inflammatory response | Binding of professional phagocytic cells | FGR, LSP1, NOTCH2, TLR4 | 4 |
Inflammatory response | Immune response of cells | CARD9, CLEC7A, ETS2, FGR, MRC1, SCARF1, MYO7A, TLR4 | 8 |
Antimicrobial response, inflammatory response | Antimicrobial response | CARD9, CLEC7A, FGR, LYST, NLRC4, TLR4 | 6 |
Inflammatory response | Innate immune response | CARD9, CLEC7A, TLR4, TRIM59 | 4 |
Cellular function and maintenance, inflammatory response | Phagocytosis | CLEC7A, ETS2, FGR, MRC1, MYO7A, TLR4, TPCN2 | 7 |
Cell-to-cell signaling and interaction, cellular growth and proliferation, hematological system development and function, inflammatory response | Stimulation of phagocytes | IL4R, TLR4 | 2 |
Antimicrobial response, humoral immune response, inflammatory response | Antifungal response | CARD9, CLEC7A | 2 |
Cell-to-cell signaling and interaction, cellular function and maintenance, inflammatory response | Phagocytosis of cells | CLEC7A, ETS2, FGR, MRC1,MYO7A, TLR4 | 6 |
Table 13 Immunosuppression-independent gene signatures predicting tolerance[134]
Symbol | Gene name | Molecular function | Biological processes |
ATXN3 ↓ | Ataxin 3 | Ubiquitin-specific protease activity | Protein metabolism |
BCLA1 ↓ | BCL2-related protein A1 | Receptor signaling complex scaffold activity | Apoptosis |
EEF1A1 ↓ | Eukaryotic translation elongation factor 1 alpha 1 | Transcription regulator activity | Regulation of cell cycle |
GEMIN7 ↑ | Gem associated protein 9 | Ribonucleoprotein | Regulation of nucleobase, nucleosides, nucleotide and nucleic acid metabolism |
IGLC1 ↑ | Immunoglobulin lambda constant 1 | Antigen binding | Immune response |
MS4A4A ↑ | Membrane-spanning 4-domains, subfamily A, member 4A | - - - | - - - |
NFκBIA ↑ | Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha | Transcription regulator activity | Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
RAB40C ↑ | RAB40C, member of RAS oncogene family | GTPase activity | Cell communication, signal transduction |
TNFAIP3 ↓ | Tumor necrosis factor, alpha-induced protein 3 | Transcription regulator activity | Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
- Citation: Salvadori M, Tsalouchos A. Biomarkers in renal transplantation: An updated review. World J Transplant 2017; 7(3): 161-178
- URL: https://www.wjgnet.com/2220-3230/full/v7/i3/161.htm
- DOI: https://dx.doi.org/10.5500/wjt.v7.i3.161